UBS Group
MAIA icon

UBS Group’s MAIA Biotechnology MAIA Stock Holding History

UBS Group’s Portfolio MAIA Stock Details MAIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.1K Sell
33,435
-18,482
-36% -$24.5K ﹤0.01% 7585
2026
Q1 		$72.7K Buy
51,917
+49,747
+2,292% +$91.7K ﹤0.01% 7157
2025
Q4 		$3.32K Buy
+2,170
New +$2.83K ﹤0.01% 9051
2025
Q3 		– Sell
-2,120
Closed -$3.82K – 10675
2025
Q2 		$3.82K Buy
2,120
+1,820
+607% +$3.26K ﹤0.01% 9318
2025
Q1 		$459 Buy
+300
New +$555 ﹤0.01% 9772
2024
Q4 		– Sell
-16,685
Closed -$46.9K – 10213
2024
Q3 		$46.9K Buy
+16,685
New +$52K ﹤0.01% 6863
2024
Q1 		– Sell
-998
Closed -$1.17K – 9743
2023
Q4 		$1.17K Buy
998
+865
+650% +$1.4K ﹤0.01% 8387
2023
Q3 		$293 Buy
+133
New +$263 ﹤0.01% 8612
2023
Q2 		– Sell
-3,949
Closed -$13.7K – 9341
2023
Q1 		$13.7K Buy
3,949
+919
+30% +$3.78K ﹤0.01% 7385
2022
Q4 		$10.6K Sell
3,030
-1,558
-34% -$5.39K ﹤0.01% 8487
2022
Q3 		$15K Buy
+4,588
New +$19.4K ﹤0.01% 7810

Other funds holding MAIA

SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $643M AUM 21% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group's MAIA Position: Q2 2026 in Review

UBS Group reduced its MAIA Biotechnology (MAIA) stake by 36% in Q2 2026, selling an estimated $24.5K and leaving 33,435 shares worth $48.1K. The position accounts for ﹤0.01% of the portfolio, ranked #7585.

UBS Group first reported a position in MAIA in Q3 2022 and has held it in 11 quarters since. The position peaked at $72.7K in Q1 2026. 36 funds tracked by Wall St. Rank hold MAIA as of Q2 2026.

  • UBS Group held 33,435 shares of MAIA Biotechnology worth $48.1K as of Q2 2026.
  • UBS Group sold 18,482 MAIA Biotechnology shares in Q2 2026, an estimated $24.5K.
  • MAIA Biotechnology made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7585 holding.
  • UBS Group first reported a position in MAIA Biotechnology in Q3 2022 and has held it in 11 quarters since.
  • UBS Group's MAIA Biotechnology position peaked at $72.7K in Q1 2026.
  • 36 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.